CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands |
Jun. 30, 2018 |
Dec. 31, 2017 |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | $ 2,291 | $ 1,275 |
| Other current assets | 11 | 98 |
| Total current assets | 2,302 | 1,373 |
| Patent license rights, net | 118 | 196 |
| Total assets | 2,420 | 1,569 |
| Current liabilities | ||
| Accounts payable | 244 | 197 |
| Other accrued liabilities | 3 | 2 |
| Total current liabilities | 247 | 199 |
| Secured debt and accrued interest, net of unamortized issuance costs | 2,355 | 2,249 |
| Capstone Therapeutics Corp. Stockholders' Equity | ||
| Common Stock $.0005 par value; 150,000,000 shares authorized; 54,385,411 shares outstanding in 2018 and 2017 | 27 | 27 |
| Additional paid-in capital | 190,474 | 190,468 |
| Accumulated deficit | (190,683) | (191,374) |
| Total Capstone Therapeutics Corp. stockholders' equity (deficit) | (182) | (879) |
| Noncontrolling interest | 0 | 0 |
| Total equity | (182) | (879) |
| Total liabilities and equity | $ 2,420 | $ 1,569 |